Clinical Trial Update: An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) [Phase 2]

View source ↗

Summary

An open-label Phase 2 study of NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phelan-mcdermid Syndrome

Drugs mentioned

• NNZ-2591 (NNZ-2591)

Snippet

Sponsor: Neuren Pharmaceuticals Limited | Conditions: Phelan-McDermid Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-05-30